Scales Up In Vitro Biological Pigment Synthesis Route

🏭Background

• Entity: Hunan Xiyuan Biotechnology Co., Ltd. (registered December 2025, Changsha Tianxin District Chuanggu Industrial Park, registered capital RMB 2 million). It is a spin-off from Professor Lin Yingwu's team at the School of Chemistry and Chemical Engineering, University of South China (18 years of research precipitation). Listed on the Hunan Equity Exchange's "Mass Entrepreneurship & Innovation" Board​ in early 2026. Received Wangcheng Economic Development Zone "Wangjian Weilai" program support (RMB 200,000 special funds + RMB 100,000/year science & technology service subsidies).
• Technology Core: Protein engineering as the core, developing artificial metalloenzyme catalysts​ for in vitro biosynthesis of natural pigments. The typical example uses indole as substrate, oxidized via flavin monooxygenase-type pathways to produce indigo blue. Claims indole conversion efficiency up to 92%. Does not rely on live bacterial long-cycle fermentation.
• Cost Anchor: Synthetic chemical pigments ~RMB 220/kg; plant-extracted natural pigments RMB 500+/kg; Xiyuan's in vitro enzymatic route falls into the ~RMB 300/kg range. For downstream customers, the key selling point is up to ~40% reduction in downstream processing (DSP) costs​ (not total cost reduction by 40%, but specifically the purification/separation stage).
• Application Scope: Six domains — textile dyeing & printing, children's toys, cosmetics/personal care, food additives, coatings & inks, biological stains. Projected 2026 revenue exceeding RMB 1 million. Initial pilot in Hengyang cultural/creative products and stationery stores, then expanding to primary/secondary school channels and B-end textile/toy manufacturers.

🧫What "No Cell Cultivation, Only Enzymes" Means

Traditional microbial indigo fermentation​ is in vivo synthesis:

• Genetically engineered E. coli / Corynebacterium glutamicum fed glucose → shikimate/tryptophan pathway produces indole → intracellular FMO oxidizes to indigo.
• Indigo is hydrophobic, crystallizes inside cells, toxic to bacteria, capping yield (ETH Zurich optimal ~12 g/L).
• Product inside cells or medium requires: harvest cells → lysis/centrifugation → remove proteins/polysaccharides → organic solvent extraction → recrystallization. Down stream processing accounts for the majority of total process cost. Batch-to-batch metabolic fluctuation affects color consistency.

Xiyuan's in vitro synthesis​ "disassembles" this pathway:

• Express/purify key enzymes (or artificial metalloenzymes) separately. In a reactor, directly add substrates (indole/tryptophan/L-tryptophan, etc.) + cofactor regeneration system. Enzymes are catalysts — they don't grow, don't produce cellular waste.
• Product (indigo) is water-insoluble. After reaction, directly centrifuge/filter to collect precipitate. No cell lysis, no removal of cell debris or endotoxins.
• Academic precedents exist (Tsinghua/ETH: surface-displayed FMO + FDH cofactor regeneration; L-tryptophan three-step cascade independent of NAD(P)H). Xiyuan's contribution is engineering these frameworks into a commercially viable, scalable product.

🚰Where Does the ~40% DSP Cost Reduction Come From?

• Eliminates seed culture expansion → seed fermenter → main fermenter long-term aeration/agitation​ energy & sterility control costs (fermentation method: 30–50% of production energy consumption).
• Eliminates cell lysis, removal of cell proteins, nucleic acid/endotoxin removal​ — the most expensive steps for food/cosmetic grade pigments.
• Product is hydrophobic precipitate: solid-liquid separation reduces from 5–7 stages to 2–3 stages. Centrifugation + filtration + washing only. Solvent usage significantly reduced.
• Enzymes can be immobilized and reused (Xiyuan's artificial metalloenzyme route favors immobilization more than natural enzymes), amortizing catalyst cost.
• Batch-to-batch only needs to adjust enzyme activity & substrate purity. Color consistency superior to live fermentation​ (bacterial metabolism susceptible to phage infection/temperature drift).

Important note: "Up to ~40%" refers to downstream customer trial data​ (the cost savings when customers process the raw material before formulation), NOT​ Xiyuan's own factory total cost reduction by 40%. Xiyuan still bears enzyme expression/purification costs — it has simply shifted the heaviest DSP burden away from the end user.

🧸Why Can It Cover Six Domains ?

In vitro enzymatic method produces single-structure nature-identical pigments​ (e.g., true indican → indigo), not a bacterial mixture:

• Textile: True indigo for vat dyeing, free of benzene-based intermediate residues from synthetic indigo. Passes bluesign/OEKO-TEX.
• Toys: Heavy metal-free, aromatic amine-free. Passes EN71-3.
• Cosmetics/Food: Free of bacterial protein allergens, endotoxin-free. Qualifies as "nature-identical," cheaper than plant extraction.
• Coatings/Ink: Controllable particle size, no microbial colloid interference, stable in waterborne systems.
• Biological Stains: Research-grade high purity.

The fundamental reason it can cover six domains simultaneously: One enzyme platform, swap substrates/enzyme types to produce different pigments, with a universal DSP framework.

⚖️Assessment from an Environmental Pigment/Dye Weekly Perspective

• Signal value > current production capacity: Xiyuan's projected 2026 revenue > RMB 1 million is still student-startup scale. But it has pulled "in vitro enzymatic pigment" from academic papers (Tsinghua/ETH/ChemBioChem 2026 all have publications) into equity exchange listing + contract manufacturing trials, proving capital markets are beginning to recognize this route.
• Real competitor is not chemical dyes, but microbial fermentation pigments​ (Colorifix, LiveCO, ETH spin-offs): Xiyuan's differentiation is "lighter DSP than fermentation, cheaper than plant extraction," landing in the RMB 300/kg price band.
• Risk points: Enzyme lifespan / cofactor regeneration cost maintaining the 40% advantage at pilot/commercial scale; artificial metalloenzyme patent barriers (South China team has multiple filings, but core sequences not publicly disclosed); who assumes GMP compliance liability at contract manufacturing sites.
• Implication for textile mills: When applying for "transition finance + carbon intensity" loans in the future, suppliers that can provide in vitro enzymatic indigo + CO₂ data per unit of coloring power​ will have an easier path to A-level clean production supply chain qualification compared to traditional vat indigo suppliers.